UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q/A
Amendment No. 1
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2004
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to .
Commission File Number 0-28494
MILLENNIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
| 04-3177038 |
(State or other jurisdiction |
| (I.R.S. Employer |
of incorporation or organization) |
| Identification No.) |
40 Landsdowne Street, Cambridge, Massachusetts 02139
(Address of principal executive offices) (zip code)
(617) 679-7000
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).
Yes x No o
Number of shares of the registrant’s Common Stock, $0.001 par value, outstanding on November 4, 2004: 305,960,455
EXPLANATORY NOTE
The Company is filing this Amendment No. 1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2004, as originally filed on November 9, 2004, for the sole purpose of revising the Exhibit Index to add an Exhibit 10.5 and to file such exhibit. Also filed as exhibits with this 10-Q/A are new certifications in accordance with Rule 13a-14(a) of the Exchange Act.
This Amendment No. 1 does not change the previously reported financial statements or any of the other disclosure contained in the original Form 10-Q.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MILLENNIUM PHARMACEUTICALS, INC. | |
|
| (Registrant) |
|
|
|
Dated: November 9, 2006 |
| /s/ MARSHA H. FANUCCI |
|
| Marsha H. Fanucci |
|
| Senior Vice President and Chief Financial Officer |
|
| (principal financial and chief accounting officer) |
3
EXHIBIT INDEX
Exhibit |
| Description |
|
|
|
10.1* |
| Agreement dated August 6, 2004 between the Company and Marsha H. Fanucci |
|
|
|
10.2* |
| Agreement dated August 6, 2004 between the Company and Kenneth M. Bate |
|
|
|
10.3* |
| Offer letter agreement dated September 28, 2004 between the Company and Laurie B. Keating |
|
|
|
10.4* |
| Form of Director Stock Option Granted under 2000 Stock Incentive Plan |
|
|
|
10.5 |
| Amendment No. 1 dated July 15, 2004 to the Collaboration, Distribution and License Agreement by and between the Company and Ortho Biotech Products, L. P. |
|
|
|
31.1* |
| Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended |
|
|
|
31.2* |
| Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended |
|
|
|
31.3 |
| Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended |
|
|
|
31.4 |
| Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended |
|
|
|
32.1* |
| Statement Pursuant to 18 U.S.C. §1350 |
|
|
|
32.2* |
| Statement Pursuant to 18 U.S.C. §1350 |
* Exhibit filed with original Form 10-Q filed with the SEC on November 9, 2004.
4